Investors finally get a glimpse of CRISPR Therapeutics AG (CRSP) volume hitting the figure of 2.94 million.

CRISPR Therapeutics AG (NASDAQ: CRSP) on Friday, soared 6.77% from the previous trading day, before settling in for the closing price of $36.31. Within the past 52 weeks, CRSP’s price has moved between $30.04 and $67.88.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Annual sales at Healthcare sector company grew by 31550.17% over the past five years. The company achieved an average annual earnings per share of -22.35%. With a float of $82.80 million, this company’s outstanding shares have now reached $86.36 million.

Let’s look at the performance matrix of the company that is accounted for 393 employees. In terms of profitability, gross margin is -259.34%, operating margin of -1313.44%, and the pretax margin is -1056.74%.

CRISPR Therapeutics AG (CRSP) Insider and Institutional Ownership

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CRISPR Therapeutics AG is 4.13%, while institutional ownership is 67.69%. The most recent insider transaction that took place on Mar 21 ’25, was worth 413,578. In this transaction Chief Executive Officer of this company sold 10,031 shares at a rate of $41.23, taking the stock ownership to the 195,085 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Operating Officer sold 1,714 for $41.23, making the entire transaction worth $70,668. This insider now owns 10,544 shares in total.

CRISPR Therapeutics AG (CRSP) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around -22.35% per share during the next fiscal year.

CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators

CRISPR Therapeutics AG (CRSP) is currently performing well based on its current performance indicators. A quick ratio of 15.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 88.89.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.52, a number that is poised to hit -1.36 in the next quarter and is forecasted to reach -4.35 in one year’s time.

Technical Analysis of CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (NASDAQ: CRSP) saw its 5-day average volume 2.09 million, a negative change from its year-to-date volume of 2.18 million. As of the previous 9 days, the stock’s Stochastic %D was 65.14%. Additionally, its Average True Range was 2.23.

During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 33.78%, which indicates a significant decrease from 90.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.93% in the past 14 days, which was higher than the 63.00% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $38.04, while its 200-day Moving Average is $44.16. Nevertheless, the first resistance level for the watch stands at $39.60 in the near term. At $40.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $41.87. If the price goes on to break the first support level at $37.33, it is likely to go to the next support level at $35.88. The third support level lies at $35.06 if the price breaches the second support level.

CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats

Market capitalization of the company is 3.35 billion based on 86,364K outstanding shares. Right now, sales total 37,310 K and income totals -366,250 K. The company made 870 K in profit during its latest quarter, and -136,000 K in sales during its previous quarter.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.